688366.SH
昊海生科
SSE · Healthcare · Biotechnology · CN
CNY 29.45
−6.21%Year over year
Reported trailing growth
- Revenue
- -9.1%
- EBITDA
- —
- EBIT
- -56.1%
- EPS
- -42.9%
- Free cash flow
- -53.6%
- Operating cash flow
- -35.7%
Forward estimates
Based on analyst estimates
- Revenue
- -44.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.1%
- EBITDA
- -1.3%
- EBIT
- -2.1%
- Net income
- +11.6%
- EPS
- +1.3%
- Free cash flow
- -9.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026